Accepted Manuscript



Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155

Keisuke Mitsuoka, Aya Kita, Yoshihiro Murakami, Kenna Shirasuna, Akihiro Noda, Kentaro Yamanaka, Naoki Kaneko, Sosuke Miyoshi

PII:	S0969-8051(17)30333-5
DOI:	doi:10.1016/j.nucmedbio.2018.06.005
Reference:	NMB 8023
To appear in:	*Nuclear Medicine and Biology*
Received date:	29 September 2017
Revised date:	22 June 2018
Accepted date:	22 June 2018

Please cite this article as: Keisuke Mitsuoka, Aya Kita, Yoshihiro Murakami, Kenna Shirasuna, Akihiro Noda, Kentaro Yamanaka, Naoki Kaneko, Sosuke Miyoshi , Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155. Nmb (2018), doi:10.1016/j.nucmedbio.2018.06.005

Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [^{11}C]YM155

Keisuke Mitsuoka, Aya Kita, Yoshihiro Murakami, Kenna Shirasuna, Akihiro Noda, Kentaro Yamanaka, Naoki Kaneko, Sosuke Miyoshi*

Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan

Running Title: [^{11}C]YM155 PET imaging to assess YM155 efficacy (max. 45 characters)

***Corresponding Author:**

Sosuke Miyoshi, Ph.D.

Drug Discovery Research, Astellas Pharma Inc.

21 Miyukigaoka, Tsukuba 305-8585, Japan

Phone: +81-29-829-6476; Fax: +81-29-854-1879; E-mail: sousuke.miyoshi@astellas.com